Back to search results

Promoting Alternatives to Sulfonylureas in Type 2 Diabetes

This study aims to help people with Type 2 diabetes who are taking sulfonylurea (SU) medications explore safer treatment options. Sulfonylureas can have side effects like low blood sugar (hypoglycemia) and falls, especially in older adults, even though newer, safer medications are available. You would be given a simple prompt sheet with questions to help you talk to your doctor about your SU medication and other options. Another group will receive a general brochure about diabetes medications. The study will look at how many people have this conversation with their doctor after 12 months. You may be able to join if you are at least 45 years old, have Type 2 diabetes, are currently taking an SU medication, and have an established primary care doctor at UH. The study status is currently unclear.

Study design
This study is designed to enroll 220 participants. It is an interventional study, meaning participants will receive a specific intervention.
What's involved
You would be encouraged to use a prompt sheet to guide a conversation with your primary care provider at your next routine diabetes care visit. The primary endpoint is measured at 12 months.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed for 12 months to see if they had a conversation with their doctor about SU use and alternatives.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT05933174

Promoting Alternatives to Sulfonylureas to Improve Patient Safety in Type 2 Diabetes

Recruiting
NAAges 45+InterventionalPrevention
Ian J. Neeland, MD
~220 participants
Updated 2025-11-13 on ClinicalTrials.gov
What's tested:Prompt-sheetUsual education

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Proportion of patients who had a conversation with their primary care provider about SU use and alternatives for their diabetes management
Measured over 12 months

Conditions

Type2diabetes

Explore related trials

Type 2 Diabetes Mellitus

Where it's being run

1 sites across 1 states
Ohio1

Study leadership

  • Ian Neeland, MD · PRINCIPAL_INVESTIGATOR · University Hospital Cleveland Medical Center

Who to contact

Ian Neeland, MD
[email protected]
216-844-5965
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Age ≥ 45 years
Type 2 diabetes (diagnosed on or before 12/31/2021)
Current/active prescription for one or more SU medications
Established care (≥2 visits) with UH primary care provider (PCP) since 2021

Exclusion

Type 1 diabetes
PCP provides a reason why patient participation is inappropriate (e.g., known cost barriers without any alternatives, prior discussion with patient about alternatives, etc.)
Patient unable or unwilling to have conversation with their PCP regarding SU
Unable to provide informed consent

What this trial measures

  • Proportion of patients who had a conversation with their primary care provider about SU use and alternatives for their diabetes management12 months

    Proportion of patients who had a conversation with their primary care provider about SU use and alternatives for their diabetes management